Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015

Publisher Name :
Date: 09-Dec-2015
No. of pages: 55
Inquire Before Buying

Global Markets Direct's, ‘Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015', provides an overview of the Herpes Labialis (Oral Herpes)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Herpes Labialis (Oral Herpes) and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes)

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 4
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Labialis (Oral Herpes) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 9
Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 10
Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes 11
Herpes Labialis (Oral Herpes) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Herpes Labialis (Oral Herpes) - Products under Development by Companies 15
Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes 16
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 17
Beech Tree Labs, Inc. 17
Foamix Pharmaceuticals Ltd. 18
Mymetics Corporation 19
NanoViricides, Inc. 20
Onxeo SA 21
Shulov Innovative Science Ltd. 22
TGV-Laboratories 23
Herpes Labialis (Oral Herpes) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
acyclovir - Drug Profile 33
Mechanism of Action 33
R&D Progress 33
acyclovir - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Aspidasept - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BTL-TMLHSV - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Herpecide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
herpes simplex virus [type 1, 2] vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
herpes simplex virus [type 1, 2] vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Teg-379 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ZEP-3 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Herpes Labialis (Oral Herpes) - Recent Pipeline Updates 43
Herpes Labialis (Oral Herpes) - Dormant Projects 46
Herpes Labialis (Oral Herpes) - Discontinued Products 47
Herpes Labialis (Oral Herpes) - Product Development Milestones 48
Featured News & Press Releases 48
Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 48
Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 48
May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 49
Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 49
Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 50
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 51
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 51
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 52
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 52
Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2015 8
Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H2 2015 17
Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 18
Herpes Labialis (Oral Herpes) - Pipeline by Mymetics Corporation, H2 2015 19
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H2 2015 20
Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H2 2015 21
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd., H2 2015 22
Herpes Labialis (Oral Herpes) - Pipeline by TGV-Laboratories, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Herpes Labialis (Oral Herpes) Therapeutics - Recent Pipeline Updates, H2 2015 43
Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2015 46
Herpes Labialis (Oral Herpes) - Discontinued Products, H2 2015 47

List of Figures

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2015 8
Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 14
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Targets, H2 2015 25
Number of Products by Stage and Targets, H2 2015 25
Number of Products by Mechanism of Actions, H2 2015 27
Number of Products by Stage and Mechanism of Actions, H2 2015 27
Number of Products by Routes of Administration, H2 2015 29
Number of Products by Stage and Routes of Administration, H2 2015 29
Number of Products by Molecule Types, H2 2015 31
Number of Products by Stage and Molecule Types, H2 2015 31
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Current State of Blood Banking Market, Products, Technologies and Services
    The global blood banking and blood products market is expected to reach US$41.9 billion by 2020 with USA continuing to be the largest market worldwide. Asia-Pacific follows a close second with a projected CAGR of 9.1% during this period owing to the refining healthcare infrastructure and increase in the per capita healthcare expenditure. The major [...]
  • Global Plasma Therapy Market Research Report to 2021
    Published: 03-Aug-2016        Price: US 2900 Onwards        Pages: 103
    Notes: Sales, means the sales volume of Plasma Therapy Revenue, means the sales value of Plasma Therapy This report studies Plasma Therapy in Global market, especially in North America, Europe, China, Japan, India and Southeast Asia, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Biolife Plasma Services Cambryn Biologics LLC Biotest CSL Ltd ......
  • Europe Plasma Therapy Market Report to 2021
    Published: 03-Aug-2016        Price: US 4900 Onwards        Pages: 109
    Notes: Sales, means the sales volume of Plasma Therapy Revenue, means the sales value of Plasma Therapy This report studies sales (consumption) of Plasma Therapy in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Biolife Plasma Services Cambryn Biologics LLC Biotest ......
  • Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2016
    Published: 20-Jul-2016        Price: US 2000 Onwards        Pages: 58
    Global Markets Direct's, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2016', provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the the......
  • Sedation - Pipeline Review, H2 2016
    Published: 20-Jul-2016        Price: US 2000 Onwards        Pages: 59
    Global Markets Direct's, ‘Sedation - Pipeline Review, H2 2016', provides an overview of the Sedation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history ......
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016
    Published: 20-Jul-2016        Price: US 2000 Onwards        Pages: 75
    Global Markets Direct's, ‘Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016', provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), complete with analysis by stage ......
  • Sarcopenia - Pipeline Review, H2 2016
    Published: 20-Jul-2016        Price: US 2000 Onwards        Pages: 61
    Global Markets Direct's, ‘Sarcopenia - Pipeline Review, H2 2016', provides an overview of the Sarcopenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development hi......
  • Myotonic Dystrophy - Pipeline Review, H2 2016
    Published: 20-Jul-2016        Price: US 2000 Onwards        Pages: 60
    Global Markets Direct's, ‘Myotonic Dystrophy - Pipeline Review, H2 2016', provides an overview of the Myotonic Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete res......
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016
    Published: 20-Jul-2016        Price: US 2000 Onwards        Pages: 144
    Global Markets Direct's, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the des......
  • Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016
    Published: 20-Jul-2016        Price: US 2000 Onwards        Pages: 342
    Global Markets Direct's, ‘Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016', provides an overview of the Non-Alcoholic Steatohepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of t......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs